Alosetron (CAS 123464-89-1) – Research Grade is a high-purity chemical compound.

Alosetron is a pyrido[4,3-b]indole compound having a 5-methyl-1H-imidazol-4-ylmethyl group at the 2-position. It has a role as a serotonergic antagonist, an antiemetic and a gastrointestinal drug. It is a member of imidazoles and a pyridoindole.

Research Context

Research Applications

Alosetron is primarily studied for its therapeutic applications in managing irritable bowel syndrome (IBS), particularly in women experiencing severe diarrhea-predominant IBS. This research compound has gained attention in clinical and preclinical studies for its potential to alleviate abdominal pain, improve bowel function, and enhance overall quality of life for patients suffering from this condition. Alosetron is known under the trade name Lotronex and has been FDA-approved specifically for the treatment of IBS in women who have not responded adequately to conventional therapies.

History & Development

Alosetron was originally developed by the pharmaceutical company GlaxoSmithKline in the late 1990s. It received FDA approval in 2000 for the treatment of severe diarrhea-predominant IBS in women. The approval was a significant milestone, as it marked one of the first targeted therapies for this condition. Alosetron's design incorporates specific modifications that enhance its binding affinity to the 5-HT3 receptor, making it a potent antagonist that helps regulate gastrointestinal motility and secretion.

Mechanism of Action

Alosetron functions primarily as a selective antagonist of the 5-hydroxytryptamine (5-HT3) receptor. By binding to these receptors, Alosetron inhibits the action of serotonin, a neurotransmitter that plays a crucial role in gut motility. This inhibition leads to a decrease in gastrointestinal contractions and an increase in the absorption of fluids in the intestines, ultimately resulting in reduced diarrhea and abdominal pain. The compound's targeted action at the receptor level helps restore normal bowel function in patients with IBS.

Clinical Data

Several studies have evaluated the efficacy and safety of Alosetron in treating IBS. For instance, a Phase 3 clinical trial led by Camilleri et al. published in the American Journal of Gastroenterology demonstrated that Alosetron significantly improved bowel habits and reduced abdominal discomfort in women with diarrhea-predominant IBS. Another study conducted by Hsu et al. reported that approximately 40% of patients treated with Alosetron experienced a substantial improvement in their IBS symptoms compared to a placebo group. These studies underscore Alosetron's potential as a viable treatment option for IBS.

How It Compares

When compared to other compounds used in the management of IBS, Alosetron exhibits distinct mechanisms and applications. For example, compared to the 5-HT4 receptor agonist Tegaserod, which promotes gastrointestinal motility, Alosetron acts as an antagonist of the 5-HT3 receptor, making it suitable for patients experiencing diarrhea-predominant IBS. Additionally, while Tegaserod is associated with enhanced bowel movement frequency, Alosetron focuses on symptom relief by reducing bowel hyperactivity. Another related compound, Eluxadoline, targets both opioid receptors and the 5-HT3 receptor, providing a multifaceted approach to managing IBS. Alosetron's unique mechanism provides a targeted alternative for specific patient populations.

Solubility & Storage

Alosetron is typically reconstituted using sterile water or bacteriostatic water. For storage, the lyophilized form should be kept at a temperature below 25°C, away from light, to maintain stability. Once reconstituted, the solution should be stored at 2-8°C and used within 24 hours to ensure efficacy. Researchers emphasize the importance of adhering to these storage guidelines to prevent degradation and maintain the compound's therapeutic properties.

Future Research Directions

Future research involving Alosetron is likely to explore its potential applications beyond diarrhea-predominant IBS. Researchers are investigating its role in other gastrointestinal disorders, particularly those involving dysregulated gut motility. Additionally, there is emerging interest in examining the off-label use of Alosetron in managing symptoms of post-infectious IBS and its potential impact on quality of life in broader patient populations. Ongoing studies aim to further elucidate the long-term safety profile and efficacy of Alosetron in diverse clinical settings.